Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of soticlestat adjunctive therapy in Lennox-Gastaut syndrome
2021-002481-40Phase 3
- Sponsor
- Takeda
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Lennox-Gastaut syndrome (LGS) comparing Soticlestat adjunctive therapy with Placebo adjunctive therapy (2 arms). Primary endpoint: Percent change from baseline in major motor/drop seizure frequency per 28 days.
02
Drugs
soticlestat
03
Conditions
Lennox-Gastaut syndrome (LGS)
Beyond the preview
Go deeper on 2021-002481-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002481-40.